Drug intelligence / Profile preview

innovac IP

Development stage: Unknown
Lead developer: Avi-Mex
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**innovac IP** is an Avi-Mex veterinary, egg-derived inactivated swine influenza vaccine for prevention of swine influenza in pigs. It contains chemically inactivated swine influenza A virus antigens representing the H1N1 and H3N2 subtypes, produced in chicken embryos and supplied as an emulsified injectable preparation. The vaccine is administered by deep intramuscular injection to production pigs, replacement animals, breeding females, and boars to induce protective immune responses against swine influenza virus infection.

Brand names: innovac IP

Beyond the preview

Go deeper on innovac IP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on innovac IP.

Explore the full profile